Corporate Information

Overview

Board of Directors

Daniel J. Levangie
Chairman of the Board
John K. Bakewell
Director
Jeffrey B. Child
Director
Richard B. Emmitt
Director
Douglas W. Kohrs
Director
John L. Miclot
Director
Robert J. Palmisano
Director
Thomas E. Timbie
Director
Elizabeth H. Weatherman
Director

Executive Officers

Robert J. Palmisano
President and Chief Executive Officer
Pascal E.R. Girin
Executive Vice President and Chief Operating Officer
Shawn McCormick
Senior Vice President, Chief Financial Officer
Stacy Enxing Seng
Executive Vice President and President, Worldwide Peripheral Vascular
Kevin M. Klemz
Senior Vice President, Secretary and Chief Legal Officer
Christine R. Kowalski
Senior Vice President, Operations
Gregory Morrison
Senior Vice President, Human Resources
David H. Mowry
Senior Vice President and President, Worldwide Neurovascular
Julie D. Tracy
Senior Vice President, Chief Communications Officer
Brett A. Wall
Senior Vice President and President, International

Corporate Information

ev3 Corporate World Headquarters
ev3 Inc.
3033 Campus Drive
Plymouth, MN 55441
USA
763.398.7000
Peripheral Vascular Division
ev3 Endovascular, Inc.
3033 Campus Drive
Plymouth, Minnesota 55441
USA
763.398.7000
Neurovascular Division
ev3 Neurovascular
9775 Toledo Way
Irvine, CA 92618
USA
949.837.3700
ev3 Europe/International Headquarters
ev3 Europe SAS
106-108 rue La Boétie
75008 Paris
France
+33 156.88.59.10
Corporate Counsel
Oppenheimer Wolff & Donnelly LLP
Minneapolis, MN
Independent Registered Public Accounting Firm
Ernst & Young LLP
Minneapolis, MN
Transfer Agent
Wells Fargo Shareowner Services
161 North Concord Exchange
South St. Paul, MN 55075
651.450.4000
Investor Relations
ev3 Inc.
3033 Campus Drive
Plymouth, MN 55441
949.680.1375
Stock Listing
ev3 is traded on the NASDAQ Global Select Market under EVVV.
Annual Meeting
May 25, 2010
2:00 p.m. (CDT)
ev3 Inc.
3033 Campus Drive
Plymouth, MN 55441
763.398.7000

Statements contained in this report that relate to future, not past, events are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by words such as “expect,” “anticipate,” “plan,” “will,” “may,” “believe,” “continue,” or other words of similar meaning. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause our actual results to be materially different than those expressed in or implied by our forward-looking statements. Such uncertainties and risks include, among others, our future operating results and financial performance, fluctuations in foreign currency exchange rates, the effect of the global economic crisis, the timing of regulatory approvals and introduction of new products, market acceptance of new products, success of clinical testing, availability of third party reimbursement, impact of competitive products and pricing and effect of regulatory actions. More detailed information on these and other factors that could adversely affect our business and operating results are described in Form 10-K.